|
COPYRIGHT 2004 International Medical News Group
WASHINGTON -- An experimental monovalent vaccine against human papillomavirus strain 16 prevents cervical intraepithelial neoplasia grades 2 and 3 in young women, Constance Mao, M.D., reported at the annual Interscience Conference on Antimicrobials and Chemotherapy.
The vaccine's manufacturer, Merck, is now conducting phase III trials of a quadrivalent HPV vaccine containing oncogenic types 16 and 18 as well as condyloma-associated types 6 and 11. Those trials involve more than 25,000 people aged 9-24 years--including a small proportion of males--in 33 countries. The company anticipates filing for U.S. approval of that vaccine by the end of 2005, Eliav...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
